Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 230 de 371.

Grafa
Insurance

Marsh McLennan agency expands Montana footprint with acquisition of Seitz Insurance Agency

Marsh McLennan Agency, a subsidiary of Marsh (NYSE:MRSH), announced on April 7, 2026, the acquisition of Seitz Insurance Agency, a prominent independent firm based in Sidney, Montana, specializing in high-growth regional sectors.

Leia mais: Marsh McLennan agency expands Montana footprint with acquisition of Seitz Insurance Agency
Grafa
Technology

HEICO expands MRO footprint with majority stake in Sherwood Avionics and Accessories

HEICO (NYSE:HEI) announced on April 7, 2026, that its Flight Support Group has acquired an 80% stake in Sherwood Avionics and Accessories, a prominent Florida-based provider of maintenance, repair, and overhaul (MRO) services.

Leia mais: HEICO expands MRO footprint with majority stake in Sherwood Avionics and Accessories
Grafa
Technology

GoPro announces major restructuring plan including 23% global workforce reduction

GoPro (NASDAQ:GPRO) announced on April 7, 2026, that its Board of Directors has approved a comprehensive restructuring plan designed to significantly reduce operating costs and accelerate the company’s push toward stronger operating leverage.

Leia mais: GoPro announces major restructuring plan including 23% global workforce reduction
Grafa
Energy

SolarMax Technology reports record 296% revenue growth driven by massive BESS expansion

SolarMax Technology (NASDAQ:SMXT), a leading integrated solar energy company, announced record financial results for the fiscal year ended December 31, 2025, marked by a near-fourfold increase in revenue and a significant expansion of its energy storage pipeline.

Leia mais: SolarMax Technology reports record 296% revenue growth driven by massive BESS expansion
Grafa

Lexaria Bioscience welcomes FDA approval of Eli Lilly’s Foundayo as oral GLP-1 market expands

Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, issued a statement on April 7, 2026, applauding the U.S. Food and Drug Administration (FDA) approval of Eli Lilly’s Foundayo, the latest oral GLP-1 receptor agonist for chronic weight management in adults.

Leia mais: Lexaria Bioscience welcomes FDA approval of Eli Lilly’s Foundayo as oral GLP-1 market expands
Grafa
Technology

TransDigm finalizes $2.2B acquisition of Jet Parts Engineering and Victor Sierra Aviation

TransDigm Group (NYSE:TDG), a leading global designer, producer, and supplier of highly engineered aircraft components, announced on April 7, 2026, the successful completion of its acquisition of Jet Parts Engineering and Victor Sierra Aviation Holdings for approximately $2.2 billion in cash.

Leia mais: TransDigm finalizes $2.2B acquisition of Jet Parts Engineering and Victor Sierra Aviation
Grafa

Savara secures accelerated review in the UK for autoimmune PAP therapy MOLBREEVI

Savara (NASDAQ:SVRA), a clinical-stage biopharmaceutical company dedicated to rare respiratory diseases, announced on April 7, 2026, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its Marketing Authorisation Application (MAA) for MOLBREEVI.

Leia mais: Savara secures accelerated review in the UK for autoimmune PAP therapy MOLBREEVI
Grafa

Gilead to acquire Tubulis for $5B to accelerate next-generation cancer therapies

Gilead Sciences (NASDAQ:GILD) announced on April 7, 2026, that it has entered into a definitive agreement to acquire Tubulis GmbH, a private German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs).

Leia mais: Gilead to acquire Tubulis for $5B to accelerate next-generation cancer therapies
Grafa

Jaguar Health reports Q4 2025 results and highlights $16M strategic cash infusion

Jaguar Health (NASDAQ:JAGX), a commercial-stage pharmaceutical company focused on gastrointestinal products, released its consolidated financial results for the fourth quarter and full year ended December 31, 2025, on April 7, 2026.

Leia mais: Jaguar Health reports Q4 2025 results and highlights $16M strategic cash infusion
Grafa

FDA grants Outlook Therapeutics formal dispute resolution meeting for ONS-5010

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its Formal Dispute Resolution Request (FDRR) regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg).

Leia mais: FDA grants Outlook Therapeutics formal dispute resolution meeting for ONS-5010
Grafa

Halozyme and Vertex sign global license deal to advance Hypercon™ microparticle technology

Halozyme Therapeutics (NASDAQ:HALO) and Vertex Pharmaceuticals (NASDAQ:VRTX) announced a global exclusive collaboration and license agreement on April 7, 2026, aimed at leveraging Halozyme’s proprietary Hypercon™ microparticle technology to transform the delivery of biologic therapies.

Leia mais: Halozyme and Vertex sign global license deal to advance Hypercon™ microparticle technology
Grafa

Alzamend Neuro announces preliminary brain imaging data for lithium candidate AL001

Alzamend Neuro (NASDAQ:ALZN), a clinical-stage biopharmaceutical company focused on developing novel products for neurological disorders, reported preliminary pharmacodynamic data on April 7, 2026, from a healthy-subject study evaluating its lead candidate, AL001.

Leia mais: Alzamend Neuro announces preliminary brain imaging data for lithium candidate AL001
Grafa
Technology

Booz Allen Hamilton finalizes acquisition of Defy Security to acale AI-driven cyber solutions

Booz Allen Hamilton (NYSE:BAH) announced on April 7, 2026, the successful completion of its acquisition of Defy Security, a move aimed at consolidating its position as a dominant provider of high-speed, tech-enabled cybersecurity services for both commercial and government sectors.

Leia mais: Booz Allen Hamilton finalizes acquisition of Defy Security to acale AI-driven cyber solutions
Grafa
Technology

ASML shares fall as U.S. lawmakers propose further curbs on China exports

Shares of ASML Holding (NYSE:ASML) declined on Tuesday as investors reacted to a new legislative proposal from U.S. lawmakers that could significantly tighten restrictions on the company’s ability to sell and service advanced chipmaking equipment in China.

Leia mais: ASML shares fall as U.S. lawmakers propose further curbs on China exports
Grafa

NervGen Pharma secures FDA alignment for Phase 3 registrational trial in spinal cord injury

NervGen Pharma (NASDAQ:NGEN), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system repair, has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), gaining alignment on the design of its Phase 3 registrational study, RESTORE.

Leia mais: NervGen Pharma secures FDA alignment for Phase 3 registrational trial in spinal cord injury
Grafa

Precigen projects record Q1 revenue following permanent J-Code for PAPZIMEOS

Precigen (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of gene and cell therapies, has announced a significant acceleration in the commercial rollout of PAPZIMEOS™ (zopapogene imadenovec-drba), projecting first-quarter 2026 revenue to exceed $18 million.

Leia mais: Precigen projects record Q1 revenue following permanent J-Code for PAPZIMEOS